OGEN

Oragenics Inc. (OGEN) | Rumor.io

Oragenics

OGEN

Attention (50-day avg)0%

Attention rank (50-day avg)#3,213

Bullish sentiment (50-day avg)32%

Price to earnings ratio0.48

Market capitalization2M

Earnings per share0.98

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-9.8M

Social

What share of all stock conversation is about OGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

May 28

Oragenics, Inc. (OGEN) is mentioned in a post discussing a company's scandal and fraud, where the CEO admitted to using company funds for personal use.
A post claims OGEN is a scam and fraud company that funneled retail investor money into a public scandal product.
Another post expresses a negative opinion on OGEN, stating that shorting the stock has been a successful strategy, with the author making over 6 figures and over 1000% returns.

Generated by AI

Sentiment

Of the messages about OGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% 0	16.67% +16.67	4.76% -72.16	49.43% -21.05
Bearish	100% 0	83.33% -16.67	95.24% +72.16	50.57% +21.05

Bullish· Jan 22

$OGEN is accumulating, with a potential wave VWAP break and volume surge over $1.30 for entries.
$OGEN is experiencing a significant volume surge, breaking out of its resistance zone and showing sizzling momentum.
$OGEN has the potential to break through $3.40, with some predicting a pop to $3.80.

Bearish· Jul 16

The company's stock price has declined by 86% over the past 6 months, and with 350m shares authorized for dilution, it may continue to fall to around 20c.
The company's lack of employees, with only Janet who is busy "grifting" for a salary, may lead to further delays and a subsequent decline in the stock price to under a dollar.
The company has a long history of failure, and despite promises of a turnaround, investors have zero confidence in the company's CEO and management, leading to a guaranteed loss.

Generated by AI

Topics

Of the messages about OGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	86.73%
Controversies	—	—	0%	5.31%
Analysts	—	—	0%	0.59%
Earnings	—	—	0%	0.59%
Macro	—	—	0%	0.59%
Technical Analysis	—	—	0%	6.19%

Earnings· Nov 8

$OGEN announces earnings after close today.
Despite attention, the stock lacks near-term catalysts and is part of a family with a history of distrust.
Earnings report for $OGEN is out.

Announcements· Jul 16

Oragenics, Inc. (OGEN) has secured a U.S.-based manufacturing partner, Sterling Pharma, to support the development of its concussion drug, ONP-002.
The manufacturing agreement is expected to support the advancement of ONP-002 to Phase IIb clinical trials.
The partnership is seen as a potential game-changer for Oragenics' clinical pipeline, with the ability to streamline the company's clinical timeline.

Macro· May 12

The latest CPI reading of 3.8% has dashed hopes for a rate cut, with oil prices surging past $100.
The high inflation reading has confirmed the expectation of a hawkish Fed, led by Chair Jerome Powell.
The strong CPI data suggests that the Fed will likely maintain its current monetary policy stance.

Technical Analysis· Feb 5

$OGEN's price needs to break above $0.5323 (VWAP) with increased volume to continue an upward move towards $0.55-$0.60.
A potential bullish scenario for $OGEN includes reclaiming $0.50 and breaking $0.55 (VWAP) with volume, which could lead to a run towards $0.60-$0.63.
$OGEN's next support level could be around $0.48 if the price drops below $0.50, or around $0.46-$0.45 if it drops below $0.47.

Generated by AI

Community

Of the messages about OGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	90%	94.44%	60.81%
Newcomers	0%	10%	5.56%	39.19%

Regulars· Jul 1

Oragenics, Inc. (OGEN) has announced a public offering of up to $20 million of preferred stock and warrants, with a combined public offering price of $25.00 per share.
Regular traders have been setting up buy orders in OGEN premarket, only to be short-sold down 53% after the announcement of bad news on a reissue.
The company's stock price has been heavily manipulated, with some traders exploiting the situation to make a profit, but the stock is considered oversold and a good value at its current price.

Newcomers· Jan 23

The newcomer is concerned about the stock's bias, citing a range-bound pattern with a risk of downside movement.
The newcomer notes that the stock has failed to break out, leading to volatility compression and a weak RSI.
The newcomer identifies key levels of support and resistance, suggesting a potential bull trap risk after rejection from the highs.

Generated by AI

Presentation Highlights Clinical Translation of ONP-002 Intranasal Delivery Platform for Concussion Treatment James P. Kelly, MD, Chief Medical Officer of Oragenics, is scheduled to present in the Successful Case Studies session at the IPAC-RS 2026 Nasal Innovation Forum on Thursday, September 17, 2026Presentation is expected to address development and clinical translation of ONP-002, including the intranasal delivery platform, Phase IIa trial design, and anticipated path to U.S. clinical develo

13d agoYahoo! Finance Canada

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

SARASOTA, Fla., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biopharmaceutical company developing brain-targeted therapeutics through its proprietary intranasal delivery platform, today provided an update on its Phase IIa clinical trial, U.S. regulatory pathway, and NYSE American continued listing status. Clinical & Regulatory Momentum Continues Oragenics continues to advance ONP-002, its lead intranasal candidate for mTBI (concussion), through its Ph

1mo agoYahoo Finance

Oragenics: Q2 Earnings Snapshot

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

1mo agoYahoo Finance

Oragenics Appoints New Chief Financial Officer and Leader

Detailed price information for Oragenics Inc (OGEN-A) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about OGEN also mention

#	Name	Attention
1	IGC Pharma Inc.IGC	0.01%+0
2	vTv Therapeutics Inc. Class A Common StockVTVT	0%new
3	TTNP - Titan Pharmaceuticals, Inc.	——
4	CorMedix Inc.CRMD	0%+0
5	InspireMD, Inc.NSPR	0%new
6	GHSI - Guardion Health Sciences, Inc.	——
7	AVGR - Avinger, Inc.	——
8	China Pharma Holdings, Inc.CPHI	0%new
9	Lm Funding America Inc.LMFA	0%new
10	Inuvo Inc.INUV	0%0

Oragenics Inc.

Healthcare
Biotechnology

Oragenics Inc. is a biotechnology company that focuses on the development and commercialization of pharmaceutical products for oral health and infectious diseases. The company is engaged in the creation of novel therapies utilizing its proprietary biological platform technologies. A key area of its research is aimed at the development of antibiotics to combat resistant strains of bacteria, often addressing public health challenges that require innovative solutions. Oragenics primarily targets sectors that include pharmaceuticals, healthcare, and biotherapeutics, impacting both consumer and clinical markets. The company is headquartered in Tampa, Florida, and continues to play a significant role in pioneering research within its niche, contributing to advancements in medical science and therapeutic options. By leveraging cutting-edge research in microbiomics, Oragenics is not only integral to addressing significant health concerns but also a notable contributor to the broader biotechnology and pharmaceutical industries.

Website

Location

9015 Town Center Parkway

Lakewood Ranch, FL, 34202

United States

Social

What share of all stock conversation is about OGEN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

May 28

Oragenics, Inc. (OGEN) is mentioned in a post discussing a company's scandal and fraud, where the CEO admitted to using company funds for personal use.
A post claims OGEN is a scam and fraud company that funneled retail investor money into a public scandal product.
Another post expresses a negative opinion on OGEN, stating that shorting the stock has been a successful strategy, with the author making over 6 figures and over 1000% returns.

Generated by AI

Sentiment

Of the messages about OGEN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	0% 0	16.67% +16.67	4.76% -72.16	49.43% -21.05
Bearish	100% 0	83.33% -16.67	95.24% +72.16	50.57% +21.05

Bullish· Jan 22

$OGEN is accumulating, with a potential wave VWAP break and volume surge over $1.30 for entries.
$OGEN is experiencing a significant volume surge, breaking out of its resistance zone and showing sizzling momentum.
$OGEN has the potential to break through $3.40, with some predicting a pop to $3.80.

Bearish· Jul 16

The company's stock price has declined by 86% over the past 6 months, and with 350m shares authorized for dilution, it may continue to fall to around 20c.
The company's lack of employees, with only Janet who is busy "grifting" for a salary, may lead to further delays and a subsequent decline in the stock price to under a dollar.
The company has a long history of failure, and despite promises of a turnaround, investors have zero confidence in the company's CEO and management, leading to a guaranteed loss.

Generated by AI

Topics

Of the messages about OGEN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	86.73%
Controversies	—	—	0%	5.31%
Analysts	—	—	0%	0.59%
Earnings	—	—	0%	0.59%
Macro	—	—	0%	0.59%
Technical Analysis	—	—	0%	6.19%

Earnings· Nov 8

$OGEN announces earnings after close today.
Despite attention, the stock lacks near-term catalysts and is part of a family with a history of distrust.
Earnings report for $OGEN is out.

Announcements· Jul 16

Oragenics, Inc. (OGEN) has secured a U.S.-based manufacturing partner, Sterling Pharma, to support the development of its concussion drug, ONP-002.
The manufacturing agreement is expected to support the advancement of ONP-002 to Phase IIb clinical trials.
The partnership is seen as a potential game-changer for Oragenics' clinical pipeline, with the ability to streamline the company's clinical timeline.

Macro· May 12

The latest CPI reading of 3.8% has dashed hopes for a rate cut, with oil prices surging past $100.
The high inflation reading has confirmed the expectation of a hawkish Fed, led by Chair Jerome Powell.
The strong CPI data suggests that the Fed will likely maintain its current monetary policy stance.

Technical Analysis· Feb 5

$OGEN's price needs to break above $0.5323 (VWAP) with increased volume to continue an upward move towards $0.55-$0.60.
A potential bullish scenario for $OGEN includes reclaiming $0.50 and breaking $0.55 (VWAP) with volume, which could lead to a run towards $0.60-$0.63.
$OGEN's next support level could be around $0.48 if the price drops below $0.50, or around $0.46-$0.45 if it drops below $0.47.

Generated by AI

Community

Of the messages about OGEN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	90%	94.44%	60.81%
Newcomers	0%	10%	5.56%	39.19%

Regulars· Jul 1

Oragenics, Inc. (OGEN) has announced a public offering of up to $20 million of preferred stock and warrants, with a combined public offering price of $25.00 per share.
Regular traders have been setting up buy orders in OGEN premarket, only to be short-sold down 53% after the announcement of bad news on a reissue.
The company's stock price has been heavily manipulated, with some traders exploiting the situation to make a profit, but the stock is considered oversold and a good value at its current price.

Newcomers· Jan 23

The newcomer is concerned about the stock's bias, citing a range-bound pattern with a risk of downside movement.
The newcomer notes that the stock has failed to break out, leading to volatility compression and a weak RSI.
The newcomer identifies key levels of support and resistance, suggesting a potential bull trap risk after rejection from the highs.

Generated by AI

Oragenics

Social

May 28

Bullish· Jan 22

Bearish· Jul 16

Earnings· Nov 8

Announcements· Jul 16

Macro· May 12

Technical Analysis· Feb 5

Regulars· Jul 1

Newcomers· Jan 23

Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

Oragenics: Q2 Earnings Snapshot

Oragenics Appoints New Chief Financial Officer and Leader

Also Discussed

Oragenics Inc.

Company Information

Location

Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum

Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update

Oragenics: Q2 Earnings Snapshot

Oragenics Appoints New Chief Financial Officer and Leader

Also Discussed

Social

May 28

Bullish· Jan 22

Bearish· Jul 16

Earnings· Nov 8

Announcements· Jul 16

Macro· May 12

Technical Analysis· Feb 5

Regulars· Jul 1

Newcomers· Jan 23